What Happened at the November 17, 2025 Oral Argument
The Second Circuit panel — consisting of three federal appellate judges — heard approximately 90 minutes of argument in New York on November 17, 2025. The central question was whether Judge Denise Cote's August 2024 Daubert ruling, excluding all of plaintiffs' general causation expert witnesses, was a proper exercise of the district court's gatekeeping function — or whether it went too far, effectively substituting the judge's scientific judgment for that of qualified experts applying accepted methodology. Legal observers present at the argument reported that two of the three judges asked pointed, skeptical questions of the defense: one judge asked whether the exclusion of all experts in an MDL — without permitting any individual case-specific evidence to proceed — was consistent with Supreme Court precedent; another questioned whether the methodological concerns cited by Judge Cote were genuine Daubert failures or simply disagreements about the weight of the evidence, which is properly left to juries. Oral argument questions are not votes — but the appellate panel's visible skepticism of the MDL-wide dismissal is a meaningful signal.
What a Second Circuit Reversal Would Mean
If the Second Circuit reverses Judge Cote's ruling — even partially — it could reinstate the federal MDL, require new Daubert hearings with revised expert presentations, or remand individual cases for case-specific proceedings. A full reversal reinstating the MDL would give thousands of dismissed plaintiffs the opportunity to re-file and proceed in federal court. Even a partial reversal — reinstating only certain expert theories or allowing case-specific evidence — would be a significant development. In either scenario, the number of new filings would surge, and firms that have already evaluated and enrolled clients will be best positioned to move quickly. A ruling is expected within 6 to 12 months of the November 2025 argument — meaning late 2026 is the most likely window.
What If the Second Circuit Affirms the Dismissal?
Even if the Second Circuit affirms MDL-3043's dismissal, state court litigation in California and Illinois continues independently. State courts are not bound by the Second Circuit's ruling, and they apply their own admissibility standards. The Frye standard in California and Illinois does not require the same level of methodological scrutiny as Daubert. An affirmance would be a setback for federal plaintiffs but would not close state court doors. It would also not affect minority-tolled claims for children who have not yet turned 18 — those claims may remain viable in state court for years. The most important action for families is to consult an attorney now, regardless of the appellate outcome.
Frequently Asked Questions
Related Pages
Tylenol Liver Damage Lawsuit
Acetaminophen — the active ingredient in Tylenol — is the leading cause of acute liver failure in the United States, responsible for approximately 56,000 emergency room visits, 26,000 hospitalizations, and nearly 500 deaths each year. Lawsuits allege that McNeil Consumer Healthcare and parent company Johnson & Johnson failed to adequately warn consumers about the narrow margin between a therapeutic dose and a potentially fatal overdose. Even doses only slightly above the recommended amount, especially when combined with alcohol use or taken across multiple acetaminophen-containing products, can cause catastrophic liver damage. If you or a loved one suffered acute liver failure, liver transplant, or death linked to acetaminophen use, you may be eligible for compensation. These liver damage claims are separate from the Tylenol autism/ADHD litigation — they involve direct injury to the person who took the medication.
Learn moreLearn moreLearn moreLearn moreLearn moreLearn moreTylenol Autism Lawsuit Lawsuit
Acetaminophen — sold under the brand name Tylenol by Kenvue (formerly Johnson & Johnson) and as dozens of store-brand generics by Walmart, CVS, Walgreens, Target, Costco, Meijer, and others — was the most commonly used pain reliever during pregnancy in the United States for decades. Starting with a landmark 2018 American Journal of Epidemiology meta-analysis of 130,000 mother-child pairs, and culminating in a 2021 consensus statement signed by 91 scientists published in Nature Reviews Endocrinology, accumulating evidence linked prolonged prenatal acetaminophen exposure to significantly elevated risks of autism spectrum disorder (ASD) and attention deficit hyperactivity disorder (ADHD). The federal multidistrict litigation, MDL-3043 (In re Acetaminophen — ASD/ADHD Products Liability Litigation) in the Southern District of New York, was dismissed in August 2024 after Judge Denise L. Cote excluded all plaintiffs' general causation experts under the Daubert standard. Critically, the Second Circuit Court of Appeals heard oral arguments on November 17, 2025 — and two of the three judges on the panel openly questioned whether Judge Cote acted too aggressively in excluding the expert testimony. A reversal by the Second Circuit could reinstate thousands of federal cases. Separately, California state courts (Alameda County) and Illinois state courts (St. Clair, Madison, and Cook counties) have active acetaminophen-autism cases proceeding under the Frye admissibility standard, which does not apply the same gatekeeping test that closed the federal MDL. Store-brand acetaminophen users have the same legal claims as Tylenol brand users — the failure-to-warn theory applies equally to Walmart's Equate brand, CVS Health brand, Walgreens brand, Costco Kirkland brand, and all other private-label acetaminophen products.
View full case overview